Rafael Holdings reports Q4 net income of $1.3M; full-year loss narrows to $8.7M
Rafael Holdings, Inc.
- Q4 net income from continuing ops $1.3M ($0.06/share) vs loss of $4.6M ($0.24/share) a year ago.
- Full-year FY2023 net loss from continuing ops $8.7M ($0.36/share) vs $140.5M ($6.22/share) prior year which included large write-offs.
- Cash, cash equivalents and marketable securities of $79.2M as of July 31, 2023.
- Suspended Barer Institute activities; sold real estate for $33M net proceeds; invested in Cyclo Therapeutics (CYTH) and Day Three Labs.
- R&D expenses reduced to $1.3M in Q4 from $1.8M; G&A down to $1.4M from $3.0M.